long term growth come focu
rais po
increasingli bullish today re-affirmed guidanc solid
result in-lin biopharma peer impress perform key
growth asset stori mar concern legaci product eros
success shift convers growth product shown
combin opportunist busi develop otezla acquisit
beigen partnership astella partnership consist commerci perform
offer competit growth profil leaner larg cap biotech peer
headwind disrupt rel younger franchis
remain solid absolut growth vs repatha even aimovig
otezla amgen biosimilar expect compens revenu runoff
expos legaci brand epogen/aranesp neupogen/neulasta longer
term think slow declin legaci eros pair boost growth
expand commerci busi otezla mild-to-moder psoriasi
addit amgen biosimilar late stage pipelin
tezepelumab time-frame make attract overal growth stori
though could see near term headwind fewer prolia offic
visit resili commerci organ think easili
recov minor offset thu continu see amgen guidanc
easili achiev beatabl reiter buy
phase otezla data mild-to-moder psoriasi expect phase
data nsclc expect updat phase monotherapi data expect
may phase data tezepelumab omecamtiv mecarbil come
due improv outlook growth product rais ep
increas po
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
asco american societi clinic
return capit employ
return equiti
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base solid
outlook room beat achiev guidanc
improv sentiment near term growth fairli
appreci legaci product risk attract
valuat strong cash flow allow
addit share buyback dividend payment
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
million
po per share valu use sum part npv
analysi market pipelin drug assum rang
weight averag cost capit wacc approv drug
pipelin drug base stage approv product market life pipelin
develop termin growth rate new launch legaci
product po also reflect net cash
downsid risk price object faster expect revenu eros
legaci brand slower expect growth new drug launch clinic trial
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
